Results 131 to 140 of about 454 (240)

Single‐cell analysis reveals neuroprotective histone deacetylase inhibitor pathways

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) involves β‐amyloid (Aβ) accumulation, tau pathology, and neuroinflammation, driving cognitive decline. Despite extensive research, disease‐modifying therapies remain elusive. We integrated single‐cell RNA sequencing (scRNA‐seq), spatial transcriptomics, and in vitro validation to identify repurposable ...
Madeline Peyton   +12 more
wiley   +1 more source

From consortia discovery to biotech creation: An innovative approach to next‐gen Alzheimer's drugs

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract Alzheimer's disease (AD) research has entered a new era where public‐private partnerships are reigniting the pursuit of disease‐modifying therapies targeting mechanisms beyond amyloid and tau. This perspective outlines how Monument Biosciences was founded to advance novel therapies by translating National Institutes of Health (NIH) ‐supported ...
Sarah F. Giardina   +11 more
wiley   +1 more source

A latent measure of cultural racism and its association with US mortality and life expectancy. [PDF]

open access: yesNat Hum Behav
Akinyemiju T   +6 more
europepmc   +1 more source

Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European Countries

open access: yesHealth Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims Lower income European countries (LIECs) have more limited financial resources to cover high‐cost technologies in rare diseases than higher income European countries (HIECs). Our study explores how treatment recommendations in myelodysplastic syndrome (MDS) can be supported in LIECS by transferring real‐world evidence (RWE ...
Zoltán Kaló   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy